MDS Clinical Trial
Official title:
A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer Cell Therapy, in Subjects With Hematological Malignancies or Dysplasias
This is a single-arm, open-label, multi-center, Phase 1 study to determine safety and tolerability of an experimental therapy called NKX101 (allogeneic CAR NK cells targeting NKG2D ligands) in patients with relapsed/refractory AML or intermediate, high and very high risk relapsed/refractory MDS.
This is a dose-finding study of NKX101 and will be conducted in 2 parts: Part 1: dose finding with two dosing regimens, utilizing modified "3+3" enrollment schema. Part 2: dose expansion to further evaluate safety and tolerability, cellular kinetics, pharmacodynamics and anti-tumor response in expansion cohorts of patients with either AML or MDS. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03680677 -
Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
|
||
| Recruiting |
NCT05009537 -
Optical Genome Mapping in Hematological Malignancies
|
||
| Not yet recruiting |
NCT04110925 -
Mutational Analysis as a Prognostic and Predictive Marker of Cardiovascular (CVD) Disease in Patients With Myelodysplasia
|
N/A | |
| Terminated |
NCT04638309 -
APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)
|
Phase 1 | |
| Completed |
NCT03466320 -
DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03138395 -
iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML
|
N/A | |
| Completed |
NCT04443751 -
A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 1 | |
| Completed |
NCT02103478 -
Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)
|
Phase 1/Phase 2 | |
| Completed |
NCT00863148 -
Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)
|
Phase 2 | |
| Completed |
NCT00761449 -
Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5
|
Phase 2 | |
| Completed |
NCT00692926 -
Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells
|
Phase 1 | |
| Terminated |
NCT00176930 -
Stem Cell Transplant for Hematological Malignancy
|
N/A | |
| Completed |
NCT02214407 -
Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML
|
Phase 3 | |
| Recruiting |
NCT05582902 -
Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients
|
||
| Not yet recruiting |
NCT05024877 -
Hetrombopag for Low/Intermediate-1 Risk MDS With Thrombocytopenia
|
Phase 2/Phase 3 | |
| Completed |
NCT00321711 -
Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents
|
Phase 2 | |
| Recruiting |
NCT06156579 -
Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML
|
Phase 2 | |
| Recruiting |
NCT05226455 -
Venetoclax in Patients With MDS or AML in Relapse After AHSCT
|
Phase 1/Phase 2 | |
| Completed |
NCT01690507 -
Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML）
|
Phase 1/Phase 2 | |
| Completed |
NCT01241500 -
Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts
|
Phase 3 |